Skip to content
About
Management
Board of Directors
Scientific Advisory Board
Therapeutic Areas
Pipeline
OLX07010 in Rare Tauopathies
OLX07010 Alzheimer’s
Technology
MOA
Patents
News & Publications
Partners and Collaborators
Contact Us
Menu
Oligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling Studies
Home
>
News
>
Oligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling Studies
Print
Oligomerix
>
News
>
Oligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling Studies
Oligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling Studies
Post navigation
Previous Post
Oligomerix to Participate in the NIH Innovation Zone at 2019 BIO International Convention
Next Post
Oligomerix Awarded $2.18 Million SBIR Grant for Tau Oligomer Inhibitor for Alzheimer’s Disease and Related Disorders
vera
View posts by vera
Leave a Reply
Cancel reply
You must be
logged in
to post a comment.
Scroll to top
close ×
